Mereo BioPharma Investors Urged to Join Securities Fraud Lawsuit

The Schall Law Firm reminds investors of a class action lawsuit against Mereo BioPharma Group plc.

Mar. 20, 2026 at 8:05am

Got story updates? Submit your updates here. ›

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Mereo BioPharma Group plc (NASDAQ: MREO) for violations of securities laws. Investors who purchased the company's securities between June 5, 2023 and December 26, 2025 are encouraged to contact the firm before April 6, 2026 to discuss their rights.

Why it matters

This lawsuit alleges that Mereo BioPharma made false and misleading statements to the market about the results of its Phase 3 ORBIT and COSMIC programs, concealing negative facts that later caused investor losses when the truth was revealed.

The details

According to the complaint, Mereo BioPharma concealed negative facts about its Phase 3 ORBIT and COSMIC programs, and later revealed that neither program hit its primary endpoint. The company's public statements were therefore false and materially misleading throughout the class period, resulting in damages to investors when the truth came to light.

  • The class period is from June 5, 2023 to December 26, 2025.
  • The deadline to contact the Schall Law Firm is April 6, 2026.

The players

Mereo BioPharma Group plc

A biopharmaceutical company that develops and commercializes innovative therapeutics.

The Schall Law Firm

A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.

Brian Schall

An attorney at the Schall Law Firm who is encouraging investors to contact the firm to discuss their rights.

Got photos? Submit your photos here. ›

What they’re saying

“We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, Schall Law Firm

What’s next

The judge in the case will decide on April 6, 2026 whether to certify the class.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosures by public companies, as investors rely on this information to make informed decisions. The Schall Law Firm is encouraging affected Mereo BioPharma investors to join the lawsuit and recover their losses.